期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

国外药品监管透明度测量研究现状与启示 被引量：3

The Oversea Research Status and Implications on Transparency Measurement of Medicine Regulation
下载PDF
导出
摘要 文章通过文献研究,介绍国外药品监管透明度测量研究现状,分析总结药品监管、医疗服务等领域透明度测量的框架与内容、指标设计以及评分方法,并对我国药品监管透明度研究提出启示,旨在为国内药品监管透明度测量工具的开发提供参考。 Literature research was used to review the oversea research status on transparency measurement of medicine regulation. We analyzed and summarized the transparency measurement＇s framework, content, indexes, and scoring methods in medicine regulation, health care and other areas. Lastly, the paper presented some advices to the research of transparency t of medicine regulation in China. The paper aimed to provide reference for domestic transparency measurement scale development of medicine regulation.
作者 杨春艳 王利军 张新平
机构地区 湖北科技学院 华中科技大学同济医学院
出处 《中国卫生事业管理》 北大核心 2015年第4期268-270,共3页 Chinese Health Service Management
基金 国家自然科学基金"基于高透明导向的基层医疗卫生机构基本药物使用监管回归模型研究"(编号:71173082) 湖北科技学院校级青年项目"基层医疗卫生机构用药监管透明度测量量表开发与应用研究"(编号:KY13073) 湖北科技学院博士启动基金项目"公立医院药品使用透明监管模型研究"(编号:BK1426)
关键词 药品监管 透明度 测量 medicine regulation transparency measurement
分类号 R95 [医药卫生—药学]
  • 相关文献

参考文献23

  • 1ROSE R. Global Corruption Report 2006: Special focus on corruption and health [ M ]. London : Pluto Press. 2006.
  • 2COHEN J C,MRAZEK M F,HAWKINS L. Corruption and pharmaceuticals: Strengthe- ning good governance to improve access [ J ]. The Many Faces of Corruption : Track- ing Vulnerabilities at the Sector Level Washington DC : World Bank ,2007.
  • 3ORGANIZATION W H. Measuring transpar- ency in the public pharmaceutical sector: Assessment instrument [ J ]. Geneva: De- partments of Essential Medicines and Phar- maceutical Policies & Ethics, Equity, Trade and Human Rights,WHO,2009.
  • 4EIJFFINGER S C, GERAATS P M. How transparent are central banks? [ J]. Europe- an Journal of Political Economy, 2006,22 (1):1 -21.
  • 5FUNG A, GRAHAM M, WEIL D. Full dis-closure:The perils and promise of transpar- ency [ M ]. Cambridge University Press, 2007.
  • 6MURPHY P E,LACZNIAK G R,WOOD G. An ethical basis for relationship marketing: a virtue ethics perspective [ J ]. European Journal of Marketing, 2007,41 ( 1/2 ) : 37 -57.
  • 7VACCARO A, MADSEN P. Firm information transparency:Ethical questions in the infor- mation age [ M]. Social informatics:An in- formation society for all? In remembrance of Rob Kling. Springer. 2006 : 145 - 156.
  • 8VACCARO A, MADSEN P. Corporate dy- namic transparency: the new ICT - driven ethics? [ J]. Ethics and information tech- nology,2009,11 (2) : 113 - 122.
  • 9VACCARO A, MADSEN P. ICT and an NGO: Difficulties in attempting to be ex- tremely transparent [ J ]. Ethics and infor- mation technology, 2009, 11 (3): 221 -231.
  • 10HEBB T. The economic inefficiency of secre- cy: Pension fund investors' corporate trans- parency concerns [ J ]. Journal of Business Ethics,2006,63 (4) :385 - 405.

二级参考文献14

  • 1崔学刚.公司治理机制对公司透明度的影响——来自中国上市公司的经验数据[J].会计研究,2004(8):72-80. 被引量：265
  • 2Transparency International Global Corruption Report[R].London,Pluto Press,2006.
  • 3WHO Medicines Strategy 2004-2007:countries at the core[R].Geneva,World Health Organization,2004.
  • 4Cohen JC,Mrazek MF,Hawkins L.Corruption and Pharmaceuticals:Strengthening Good Governance to Improve Access.In Campos J,Pradhan S.ed.The Many Faces of Corruption:Tracking Vulnerabilities at the Sector Level,(pp.29-62).Washington,D.C.The World Bank,2007.
  • 5MeTA.Towards A Medicines Transparency Alliance[EB/OL].http://www.dfidhealthrc.org/Me TA/february_meeting.html,2010-02-25.
  • 6Jillian Clare Cohen.Pharmaceuticals and corruption:a risk assess-ment[R].In Global Corruption Report 2006.London:Transparency International; 2006:77-84.
  • 7MeTA.Transparency and Accountability in the Supply of Medicines[EB/OL].http://www.dfidhealthrc.org/MeTA/february_meeting.html,2010-02-25.
  • 8World Health Organization.Measuring transparency to improve good governance in the public pharmaceutical sector[R].Working document.March 2008.
  • 9Taryn Vian.Review of corruption in the health sector:theory,methods and interventions[J].Health Policy and Planning 2008;23:83-94.
  • 10MeTA.Peru[EB/OL].http://www.dfidhealthrc.org/MeTA/march_meeting.html,2010-02-25.

共引文献14

同被引文献16

  • 1Florini A. The right to know : transparency for an open world [ M ]. Co- lumbia University Press,2007.
  • 2Dapko J. Perceived Finn Transparency:Scale and Model Development [ D ] ; University of South Florida,2012.
  • 3Herrlich A. Transparency and medical interventions in vital statistics reports:Quantitative research and analysis[ D ]. the George Washington University ,2010.
  • 4Malajovich L, Alcalde M A, Castagnaro K, et al. Budget transparency on maternal health spending:a case study in five Latin American coun- tries [ J ]. Reproductive Health Matters, 2012,20 ( 39 ) : 185 - 195.
  • 5Pasquier M, Villeneuve J P. Organizational barriers to transparency : a typology and analysis of organizational behaviour tending to prevent or restrict access to information [ J ]. International Review of Administra- tive Sciences,2007,73( 1 ) :147 -162.
  • 6Ball D E, Tisocki K, HERXHEIMER A. Advertising and disclosure offunding on patient orgmfisation websites: a cross-sectional survey [ J]. BMC public health,2006,6(2) : 1.
  • 7Crowe C,Meade E E. Central bank independence and transparency:E- volution and effectiveness[ J ]. European Journal of Political Economy, 2008,24 (4) :763 - 777.
  • 8Hibbard J H ,Greene J Sofaer S ,et al. An experiment shows that a well- designed repert on costs and quality can help consumem choose highvalue he'd/th care [ J ]. Heahh Aft(Millwoot) ,2012,31 (3) :560 - 568.
  • 9Relly J E, Sabharwal M. Perceptions of transparency of government pol- icymaking:A cross- national study[ J ]. Gowernment Information Quar- terly,2009,26( 1 ) : 148 - 157.
  • 10李成,孙强,李凯,杨慧云,左根永,孟庆跃.基本药物制度实施前后安徽省乡镇卫生院处方质量分析[J].中国卫生经济,2012,31(4):68-69. 被引量：17

引证文献3

二级引证文献6

中国卫生事业管理
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部